Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas opens new Japanese research facilities

This article was originally published in Scrip

Executive Summary

Astellashas inaugurated several new facilities at its existing research site in Tsukuba, Japan. The three laboratories, office and other facilities total 85,000m2, more than doubling the floor area at the campus, and cost ¥30 billion ($286.3 million) to build. All Japanese discovery functions, including in the pharmacology and chemistry areas, will be transferred to the site next spring. The move is part of a wider restructuring of domestic R&D facilities which will see the closure of a Tokyo research centre and the concentration of development research at the Kashima site near Osaka. Astellas has also dissolved its Fujisawa Ireland subsidiary in Killorglin, Ireland, following the transfer of all functions to Astellas Ireland, its main European production operation set up in 2005.

You may also be interested in...



ASCO 2020: Positive Early Data For Keytruda/Lenvima In Liver, Kidney Cancer

Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.

Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro

Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.

ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS

Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.

Topics

Related Companies

UsernamePublicRestriction

Register

AG002833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel